Form 4: Akero Therapeutics Chief Scientific Officer Acquires Shares Through Employee Stock Purchase Plan

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, acquired 1,064 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.

Summary

• On June 28, 2024, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, acquired 1,064 shares of the company's common stock.
• The acquisition was made through the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan.
• The price per share was $19.941, representing 85% of the closing price of Akero Therapeutics' common stock on that date.
• Following the transaction, Rolph directly owns 181,242 shares of Akero Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of shares by an executive is generally viewed positively, but this is a routine transaction through an employee stock purchase plan.

Positives

• The acquisition of shares by a key executive demonstrates confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their investment in the company's stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it reflects insider confidence.

Key Dates